Nathalie Maubon

Nathalie Maubon has a strong background in HTS/HCS (High Throughput Screening/High Content Screening) and eADME (Absorption, Distribution, Metabolism, and Excretion) research. Nathalie founded HCS Pharma in 2014 and currently holds positions as CEO and CSO. Prior to founding their own company, they served as COO and test facility manager at Xenoblis from 2013 to 2014. Nathalie also worked at Abbott Laboratories as a senior scientist in HTS/HCS from 2010 to 2012. Before Abbott, they held positions at Solvay Pharmaceuticals, Fournier Pharma, and ENSAT/INP, where they conducted research and led teams in the field of toxicology, cancerology, and eADME. At Solvay Pharmaceuticals, they were responsible for establishing cellular imaging in high Content Screening, as well as new assays and targets. Nathalie also established cells production automation and reorganized the IT area and lab operations. At Fournier Pharma, they managed the eADME department and implemented data stream and information systems. Nathalie Maubon began their career as a research engineer in toxicology and cancerology at ENSAT/INP.

Nathalie Maubon's education history began in 1993 when they enrolled at the University of Lille 1 Sciences and Technology, where they obtained a Bachelor's degree in Biochemistry in 1995. Nathalie then continued their studies at the same institution and completed two Maîtrise degrees, one in Biochemistry with a specialization in genetics and the other in Cellular Biology and Physiology with a specialization in molecular and cellular genetics, from 1995 to 1996. In 1996, they pursued a Master's degree in Biology-Health at the University of Lille 1 Sciences and Technology, which they completed in 1997. Finally, Nathalie Maubon earned a PhD in Oncology and Toxicology from ENSAT, where they studied from 1998 to 2001.